A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC)

doi:10.21037/tgh.2016.03.10

Editorial

. 2016 Mar 16:1:2.

doi: 10.21037/tgh.2016.03.10. eCollection 2016.

A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC)

Kirti Shetty¹, Aiwu Ruth He²

Affiliations

¹ Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, USA.
² Lombardi Cancer Center, Georgetown University Hospital, USA.

PMID: 28138570
PMCID: PMC5244741
DOI: 10.21037/tgh.2016.03.10

Editorial

A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC)

Kirti Shetty et al. Transl Gastroenterol Hepatol. 2016.

. 2016 Mar 16:1:2.

doi: 10.21037/tgh.2016.03.10. eCollection 2016.

Authors

Kirti Shetty¹, Aiwu Ruth He²

Affiliations

¹ Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, USA.
² Lombardi Cancer Center, Georgetown University Hospital, USA.

PMID: 28138570
PMCID: PMC5244741
DOI: 10.21037/tgh.2016.03.10

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Cited by

Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.
Song F, Zhang Z, Liu W, Xu T, Hu X, Wang Q, Zhang W, Ge L, Zhang C, Hu Q, Qin H, Zhang S, Ren X, Fan W, Zhang Y, Huang P. Song F, et al. Adv Sci (Weinh). 2024 Jun;11(24):e2306671. doi: 10.1002/advs.202306671. Epub 2024 Apr 19. Adv Sci (Weinh). 2024. PMID: 38639383 Free PMC article.
CHML promotes liver cancer metastasis by facilitating Rab14 recycle.
Chen TW, Yin FF, Yuan YM, Guan DX, Zhang E, Zhang FK, Jiang H, Ma N, Wang JJ, Ni QZ, Qiu L, Feng J, Zhang XL, Bao Y, Wang K, Cheng SQ, Wang XF, Wang X, Li JJ, Xie D. Chen TW, et al. Nat Commun. 2019 Jun 7;10(1):2510. doi: 10.1038/s41467-019-10364-0. Nat Commun. 2019. PMID: 31175290 Free PMC article.

References

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. 10.1002/ijc.25516 - DOI - PubMed
1. Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. 10.1159/000343828 - DOI - PMC - PubMed
1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed
1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 10.1016/S1470-2045(08)70285-7 - DOI - PubMed
1. Kim HY, Park JW. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. Dig Dis 2011;29:303-9. 10.1159/000327563 - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. 10.1002/ijc.25516 - DOI - PubMed

[2] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. 10.1002/ijc.25516 - DOI - PubMed

[3] Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. 10.1159/000343828 - DOI - PMC - PubMed

[4] Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. 10.1159/000343828 - DOI - PMC - PubMed

[5] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed

[6] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed

[7] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 10.1016/S1470-2045(08)70285-7 - DOI - PubMed

[8] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 10.1016/S1470-2045(08)70285-7 - DOI - PubMed

[9] Kim HY, Park JW. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. Dig Dis 2011;29:303-9. 10.1159/000327563 - DOI - PubMed

[10] Kim HY, Park JW. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. Dig Dis 2011;29:303-9. 10.1159/000327563 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC)

Affiliations

A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC)

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources